United States

Profile: AstraZeneca PLC (AZN)

AZN on New York Consolidated

16 Mar 2018
Change (% chg)

$0.77 (+2.28%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four additional indications for projects that have reached phase II, and seven oncology combination projects. It has approximately 30 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

The Company's oncology projects include Immuno-oncology franchise; Tumour drivers and resistance mechanisms franchise; Deoxyribonucleic acid (DNA) damage response franchise, and Antibody-drug conjugates franchise. Immuno-oncology franchise includes Durvalumab (MEDI4736), which is an anti-Programmed death-ligand 1 (anti-PD-L1) antibody in Phase III development for non-small cell lung cancer (NSCLC) as a monotherapy and in combination with tremelimumab, an anti-Cytotoxic T-Lymphocyte-Associated protein 4 antibody; MEDI0680, which is an antiprogrammed cell death protein 1 (PD-1) Monoclonal Antibody (MAb) that may help promote an anti-tumor immune response by blocking the interactions between PD-1 and its ligands, and Other immuno-oncology agents in early development, which include MEDI6383, a human tumor necrosis factor receptor superfamily, member 4 (OX40) agonist; MEDI9447 targeting ecto-5'-nucleotidase (cluster of differentiation 73 (CD73)) and MEDI1873 targeting glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Tumor drivers and resistance mechanisms franchise includes Tagrisso, which is a selective, irreversible inhibitor of the activating sensitizing epidermal growth factor receptor (EGFR) mutation and the resistance mutation T790M; Selumetinib, which is a mitogen-activated protein kinase inhibitor in Phase III development for adjuvant differentiated thyroid cancer; Cediranib, which is an orally administered multi-Vascular Endothelial Growth Factor receptor (VEGFR) inhibitor tested in combination with Lynparza in patients with platinumsensitive relapsed (PSR) ovarian cancer and platinum-resistant/refractory (PRR) ovarian cancer; AZD5363, which is a protein kinase B (AKT) inhibitor in Phase II development for breast and prostate cancer; Savolitinib (AZD6094), which is a hepatocyte growth factor receptor (c-MET) inhibitor; Vistusertib (AZD2014), which is an inhibitor of the mammalian target of rapamycin serine/threonine kinase (TORC1, TORC2) and is in Phase II development for the treatment of solid and hematological tumors; AZD9496, which is a selective estrogen receptor down-regulator (SERD) in Phase I development for the treatment of breast cancer, and Acalabrutinib, which is a Bruton's tyrosine kinase (BTK) inhibitor in Phase III development in B-cell malignancies and solid tumors. DNA damage response franchise includes Lynparza, which is being evaluated in a range of Phase III trials, including BRCAm adjuvant and metastatic breast cancer, gBRCAm pancreatic cancer, gBRCAm ovarian cancer and prostate cancer, and AZD1775, which is a Wee1 inhibitor in Phase II development for ovarian and other solid tumors in combination with Lynparza. Antibody-drug conjugates franchise includes Moxetumomab pasudotox, which is an anti-CD22 recombinant immunotoxin, and MEDI4276, which is a HER2 bispecific ADC.

The Company's Cardiovascular & Metabolic Disease pipeline includes Brilinta/Brilique, which is an oral antiplatelet treatment for acute coronary syndromes (ACS); Forxiga, which is used for the treatment of heart failure; MEDI4166 for diabetes/cardiovascular disease; MEDI0382 for diabetes/obesity, and AZD4076 for non-alcoholic steatohepatitis. Its marketed products for cardiovascular disease include Atacand/Atacand HCT/Atacand Plus (candesartan cilexetil), Brilinta/Brilique (ticagrelor), Crestor (rosuvastatin calcium), Imdur (isosorbide mononitrate), Plendil (felodipine), Seloken/Toprol-XL (metoprolol succinate), Tenormin (atenolol) and Zestril (lisinopril dihydrate). Its marketed products for Metabolic disease include Bydureon (exenatide XR injectable suspension), Byetta (exenatide injection), Farxiga/Forxiga (dapagliflozin), Kombiglyze XR (saxagliptin and metformin HCl), Komboglyze (saxagliptin and metformin HCl), Onglyza (saxagliptin), Qtern (saxagliptin/dapagliflozin), Symlin (pramlintide acetate), Xigduo (dapagliflozin and metformin HCI) and Xigduo XR (dapagliflozin and metformin HCI).

The Company's respiratory pipeline in chronic obstructive pulmonary disease (COPD) includes PT010, which is a twice-daily triple inhaled medicine combination, including long-acting muscarinic antagonist (LAMA)/ long-acting beta2-adrenergic receptor agonist (LABA)/ inhaled corticosteroid (ICS). PT010 is composed of glycopyrrolate, formoterol and budesonide (key components of Symbicort and Bevespi Aerosphere) in late-stage development. The Company's respiratory pipeline in chronic obstructive pulmonary disease (COPD) also includes Benralizumab, which is an anti-eosinophil MAb that directly induces cellular apoptosis, which results in rapid and near-complete depletion of eosinophils, and Tralokinumab, which is an investigational MAb that binds to Interleukin (IL)-13. PT010 is delivered in a pressurized metered-dose inhaler (pMDI) using the Aerosphere Technology. Its marketed products include Accolate (zafirlukast), Bevespi Aerosphere (glycopyrrolate and formoterol fumarate), Bricanyl Respules (terbutaline), Bricanyl Turbuhaler (terbutaline), Daliresp/Daxas (roflumilast), Duaklir Genuair (aclidinium/formoterol), Eklira Genuair/Tudorza Pressair (aclidinium), Oxis Turbuhaler (formoterol), Pulmicort Turbuhaler/Pulmicort Flexhaler (budesonide), Pulmicort Respules (budesonide), Symbicort pMDI (budesonide/formoterol) and Symbicort Turbuhaler (budesonide/formoterol).

The Company's Other Disease Areas pipeline progressions include Anifrolumab, which is a developmental MAb that inhibits the activity of all type I interferon (IFN) receptors, which play a central role in lupus; Brodalumab, which is a human MAb that targets the IL-17 receptor; Zurampic, which inhibits the urate transporter, URAT1, which is responsible for the majority of the renal reabsorption of uric acid; Verinurad (RDEA3170), which is a selective uric acid reabsorption inhibitor, also intended for use as a combination uratelowering therapy with xanthine oxidase inhibitors (XOIs); MEDI8852, which is an investigational human MAb for the treatment of patients hospitalized with Type A strain influenza and MEDI8897, which is an extended half-life MAb for the prevention of serious respiratory disease caused by respiratory syncytial virus (RSV) in infants.

Company Address

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
P: +4420.73045000
F: +4420.76048151

Company Web Links